Plain-English translation of NCT07079475 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two medications— and —in people with advanced non-small cell lung cancer that has specific genetic changes (EGFR mutations). This is the first time these two drugs are being tested together in patients. The study will measure how safe the combination is, what side effects occur, how the body processes these medications, and whether they can slow or shrink the cancer.
Many patients with this type of lung cancer stop responding to current standard treatments over time. This trial exists to see if combining this medication with another approach might help patients whose cancer has become resistant to existing therapies.
You likely qualify if…
You likely don't qualify if…
You would take two oral medications (pills) together as part of the study. You would visit the clinic regularly so doctors can check how you're responding to treatment, monitor for side effects, and draw blood samples to measure medication levels in your body. The study involves different patient groups with slightly different entry requirements—some participants must have progressed on previous treatments, while others may be treatment-naive (newly diagnosed). Throughout the study, researchers will assess whether your tumors are shrinking and track how well you tolerate the medication.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
China